Cosentyx (secukinumab) Sensoready pen — United Healthcare

Psoriatic Arthritis

Initial criteria

Diagnosis of active psoriatic arthritis
One of the following: (a) History of failure to a 3-month trial of methotrexate at maximally indicated dose, unless contraindicated or adverse effects OR (b) Previously treated with a targeted immunomodulator FDA-approved for psoriatic arthritis (e.g., Cimzia, adalimumab, Simponi, Stelara, Tremfya, Xeljanz/Xeljanz XR, Otezla, Skyrizi, Rinvoq, Enbrel) OR (c) Currently on Cosentyx therapy with documentation and has not received manufacturer supplied sample or assistance
Not receiving Cosentyx in combination with another targeted immunomodulator [Enbrel, Cimzia, Simponi, Orencia, adalimumab, Stelara, Skyrizi, Tremfya, Taltz, Xeljanz, Olumiant, Rinvoq, Otezla]
Prescribed by or in consultation with a rheumatologist or dermatologist

Documentation of positive clinical response to Cosentyx therapy
Not receiving Cosentyx in combination with another targeted immunomodulator [Enbrel, Cimzia, Simponi, Orencia, adalimumab, Stelara, Skyrizi, Tremfya, Taltz, Xeljanz, Olumiant, Rinvoq, Otezla]

12 months